149 related articles for article (PubMed ID: 37921680)
1. Nivolumab/Relatlimab-rmbw: A Novel Dual Combination Therapy to Treat Adult and Pediatric Patients With Unresectable or Metastatic Melanoma.
Thomas B; Burns M; Pervanas H; Ciurescu D; Dima L
Am J Ther; 2023 Nov-Dec 01; 30(6):e526-e534. PubMed ID: 37921680
[TBL] [Abstract][Full Text] [Related]
2. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Tawbi HA; Schadendorf D; Lipson EJ; Ascierto PA; Matamala L; Castillo Gutiérrez E; Rutkowski P; Gogas HJ; Lao CD; De Menezes JJ; Dalle S; Arance A; Grob JJ; Srivastava S; Abaskharoun M; Hamilton M; Keidel S; Simonsen KL; Sobiesk AM; Li B; Hodi FS; Long GV;
N Engl J Med; 2022 Jan; 386(1):24-34. PubMed ID: 34986285
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma.
Phillips AL; Reeves DJ
Ann Pharmacother; 2023 Jun; 57(6):738-745. PubMed ID: 36268952
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab Plus Relatlimab: First Approval.
Paik J
Drugs; 2022 Jun; 82(8):925-931. PubMed ID: 35543970
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial.
Schadendorf D; Tawbi H; Lipson EJ; Stephen Hodi F; Rutkowski P; Gogas H; Lao CD; Grob JJ; Moshyk A; Lord-Bessen J; Hamilton M; Guo S; Shi L; Keidel S; Long GV
Eur J Cancer; 2023 Jul; 187():164-173. PubMed ID: 37167764
[TBL] [Abstract][Full Text] [Related]
6. The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma.
Albrecht LJ; Livingstone E; Zimmer L; Schadendorf D
Curr Oncol Rep; 2023 Jun; 25(6):647-657. PubMed ID: 37004702
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
Ascierto PA; Lipson EJ; Dummer R; Larkin J; Long GV; Sanborn RE; Chiarion-Sileni V; Dréno B; Dalle S; Schadendorf D; Callahan MK; Nyakas M; Atkinson V; Gomez-Roca CA; Yamazaki N; Tawbi HA; Sarkis N; Warad D; Dolfi S; Mitra P; Suryawanshi S; Grob JJ
J Clin Oncol; 2023 May; 41(15):2724-2735. PubMed ID: 36780608
[TBL] [Abstract][Full Text] [Related]
8. Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis.
Boutros A; Tanda ET; Croce E; Catalano F; Ceppi M; Bruzzone M; Cecchi F; Arecco L; Fraguglia M; Pronzato P; Genova C; Del Mastro L; Lambertini M; Spagnolo F
Eur J Cancer; 2023 Jul; 188():64-79. PubMed ID: 37196485
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma.
Koseła-Paterczyk H; Rutkowski P
Expert Opin Biol Ther; 2023 May; 23(5):383-388. PubMed ID: 37200112
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
[TBL] [Abstract][Full Text] [Related]
11. Relatlimab-nivolumab: A practical overview for dermatologists.
Mullick N; Nambudiri VE
J Am Acad Dermatol; 2023 Nov; 89(5):1031-1037. PubMed ID: 37343829
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab and relatlimab for the treatment of melanoma.
Chen XY; Li YD; Xie Y; Cao LQ; Ashby CR; Zhao H; Chen ZS
Drugs Today (Barc); 2023 Feb; 59(2):91-104. PubMed ID: 36811409
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression-free survival based on reconstructed individual patient data.
Ossato A; Damuzzo V; Baldo P; Mengato D; Chiumente M; Messori A
Cancer Med; 2023 Feb; 12(3):2155-2165. PubMed ID: 35920297
[TBL] [Abstract][Full Text] [Related]
16. Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY.
Raschi E; Comito F; Massari F; Gelsomino F
Immunotherapy; 2023 Feb; 15(2):85-91. PubMed ID: 36628573
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Amaria RN; Postow M; Burton EM; Tetzlaff MT; Ross MI; Torres-Cabala C; Glitza IC; Duan F; Milton DR; Busam K; Simpson L; McQuade JL; Wong MK; Gershenwald JE; Lee JE; Goepfert RP; Keung EZ; Fisher SB; Betof-Warner A; Shoushtari AN; Callahan M; Coit D; Bartlett EK; Bello D; Momtaz P; Nicholas C; Gu A; Zhang X; Korivi BR; Patnana M; Patel SP; Diab A; Lucci A; Prieto VG; Davies MA; Allison JP; Sharma P; Wargo JA; Ariyan C; Tawbi HA
Nature; 2022 Nov; 611(7934):155-160. PubMed ID: 36289334
[TBL] [Abstract][Full Text] [Related]
18. The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.
Mallardo D; Woodford R; Menzies AM; Zimmer L; Williamson A; Ramelyte E; Dimitriou F; Wicky A; Wallace R; Mallardo M; Cortellini A; Budillon A; Atkinson V; Sandhu S; Olivier M; Dummer R; Lorigan P; Schadendorf D; Long GV; Simeone E; Ascierto PA
J Transl Med; 2023 Oct; 21(1):753. PubMed ID: 37880788
[TBL] [Abstract][Full Text] [Related]
19. Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.
Shoushtari AN; Friedman CF; Navid-Azarbaijani P; Postow MA; Callahan MK; Momtaz P; Panageas KS; Wolchok JD; Chapman PB
JAMA Oncol; 2018 Jan; 4(1):98-101. PubMed ID: 28817755
[TBL] [Abstract][Full Text] [Related]
20. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]